From here on, a potential biomarker of response to anti-PD-1/anti-PD-L1 therapy can be considered the expression of PD-L1 on CTC surface, as proposed for breast cancer, non-small cell lung cancer (NCLS) and also metastatic melanoma (61, 62). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.